DANIEL NIKNAM: Open Payments
NPI 1598262073 · INGLEWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,826 in 77 payments from 21 companies in 2025. Trend: 2023 $1,073 · 2024 $1,367 · 2025 $1,826
Food & beverage: $1,783Education: $43
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 25 | $533 |
| Lundbeck LLC | 9 | $242 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $174 |
| Electromed, Inc. | 6 | $80 |
| Actelion Pharmaceuticals US, Inc. | 3 | $79 |
| GENZYME CORPORATION | 2 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $67 |
| Aimmune Therapeutics, Inc. | 2 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
| Insmed, Inc. | 2 | $55 |
Products named: NUCALA, REXULTI, TRELEGY ELLIPTA, Kerendia, SMARTVEST, DUPIXENT, OFEV, VOWST.
Industry payments across CA — which companies pay providers there.
